24/7 Market News Snapshot 07 October, 2025 – Adicet Bio, Inc. Common Stock (NASDAQ:ACET)

October 7, 2025

DENVER, Colo., 07 October, 2025 (www.247marketnews.com) – (Nasdaq:ACET) are discussed in this article.
Adicet Bio, Inc. (Nasdaq:ACET), a clinical-stage biotechnology firm focused on the development of innovative allogeneic gamma delta T cell therapies for cancer and autoimmune diseases, is experiencing mixed investor sentiment as it embarks on a pivotal financial initiative. The company recently announced the pricing of an underwritten registered direct offering, which includes 70,001,000 shares of common stock and pre-funded warrants for an additional 10,000,000 shares. Priced at $1.00 per share, with pre-funded warrants offered at $0.9999 each, this strategic financing is projected to generate gross proceeds of approximately $80 million, significantly bolstering Adicet’s capacity to fuel its groundbreaking therapeutic research.

Despite this positive development, Adicet’s stock faced notable bearish momentum recently, opening at $0.946 before experiencing a decline, trading down 16.8% at $0.832. A substantial trading volume of 25.84 million shares underscores heightened investor activity that appears to signal strong selling pressure amidst concerns regarding the company’s fundamentals or general market sentiment. As technical indicators suggest the potential for oversold conditions, the stock’s support level around $0.80 will be critical to watch; a breach here could lead to further declines. On the upside, resistance near the $0.95 area might prove crucial for any recovery attempts.

The offering, which is set to close around October 8, 2025, remains contingent on standard closing conditions. Jefferies and Guggenheim Securities act as joint book-running managers, supported by Wedbush PacGrow and H.C. Wainwright & Co. as lead managers, enhancing the strategic execution of this vital funding initiative. Adicet continues to invite stakeholders to remain engaged as it advances the development of effective “off-the-shelf” CAR T therapies, aiming to transform the treatment paradigm for challenging diseases.

Related news for (ACET)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.